Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have chosen to take part voluntarily and have signed a consent form
• People aged 18 to 75 years, of any gender
• People with a life expectancy of at least 3 months
• People with a general health and activity level rated as ECOG 0, 1, or 2; people rated ECOG 3 may be considered if the decline in health is caused by the lymphoma itself and the treating doctor believes treatment could help
• People with a confirmed laboratory diagnosis of grade I, II, or IIIa follicular lymphoma (a slow-growing type of blood cancer) that has not been previously treated, is at an advanced stage (stage III or IV), and meets specific criteria indicating that treatment is needed (known as GELF criteria)
• People who have measurable or assessable areas of lymphoma that can be tracked during the trial
• People with adequate blood cell counts — specifically, a type of infection-fighting white blood cell (neutrophils) above a certain level, or platelets above a certain level; exceptions may apply if low counts are caused by the lymphoma itself and the doctor believes they may improve
• People with liver and kidney function results within acceptable ranges as assessed by blood tests (confirm with trial site for specific values)
• People whose kidneys are filtering at a rate of at least 30 mL/min, calculated using a standard formula
• People who are able to attend study visits and follow the trial's requirements
• People of childbearing potential who agree to use effective contraception during the trial and for 24 months after treatment ends; women of childbearing potential must have a negative pregnancy test before starting treatment

Who may not be able to join:

• People with grade IIIb follicular lymphoma or follicular lymphoma that has transformed into a more aggressive type
• People who have received any treatment directed at their lymphoma within the 2 weeks before enrolling
• People with certain serious medical conditions, including:
  • High blood pressure that remains poorly controlled despite lifestyle changes and treatment with at least three maximum-dose blood pressure medications for 4 or more weeks, or requiring four or more medications to keep it under control
  • Heart failure that is moderate to severe (NYHA class 3 or 4) within the 6 months before screening
  • A heart pumping function (left ventricular ejection fraction) below 50%
  • Coronary artery disease causing symptoms such as chest pain, palpitations, or fatigue, or requiring medication
  • A very slow heart rate (below 40 beats per minute), low blood pressure, dizziness, or fainting; people with a history of irregular heart rhythms will require a heart assessment
  • An active bacterial, viral, fungal, or other infection (other than a nail fungal infection), or a significant infection within 2 weeks before the first dose
  • Moderate to severe liver disease (rated Child-Pugh B or C)
  • Active bleeding within the 2 months before screening, or a significant tendency to bleed as judged by the treating doctor
  • Lung conditions that affect breathing function (such as pulmonary fibrosis or medication-related lung inflammation) that the treating doctor considers too risky
  • Any mental health or cognitive condition that may affect a person's ability to understand the consent process, follow the trial protocol, or participate consistently
• People with a known active hepatitis C infection, HIV infection, or other conditions that weaken the immune system
• People whose lymphoma has spread to the brain or spinal cord
• People who have been diagnosed with or treated for another cancer, except: cancers treated with the aim of cure with no sign of return for 5 or more years before enrolling; adequately treated non-melanoma basal cell skin cancer with no evidence of disease; or adequately treated cervical carcinoma in situ with no evidence of disease
• People with a known allergy or sensitivity to any of the study drugs
• Women who are pregnant or breastfeeding
• People who have had a stroke or bleeding in the brain within the 6 months before enrolling
• People who require ongoing blood-thinning treatment with warfarin or similar vitamin K antagonist medications
• People who require ongoing use of certain strong medications that affect how the body processes drugs (strong CYP3A inhibitors) (confirm specific medications with trial site)
• People who have received a live attenuated vaccine within the 4 weeks before entering the trial

Important: Always verify eligibility with the trial site directly before applying.